208 related articles for article (PubMed ID: 27744089)
61. Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction.
Buckley LF; Canada JM; Del Buono MG; Carbone S; Trankle CR; Billingsley H; Kadariya D; Arena R; Van Tassell BW; Abbate A
ESC Heart Fail; 2018 Apr; 5(2):372-378. PubMed ID: 29345112
[TBL] [Abstract][Full Text] [Related]
62. Combination of ST2 and B-type natriuretic peptide in diabetic patients with acute heart failure: relation with ventricular stiffness and outcome.
Ruocco G; Evangelista I; Franci B; Lucani B; Martini S; Nuti R; Palazzuoli A
J Cardiovasc Med (Hagerstown); 2019 Feb; 20(2):81-90. PubMed ID: 30540645
[TBL] [Abstract][Full Text] [Related]
63. Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction.
Lyle MA; Iyer SR; Redfield MM; Reddy YNV; Felker GM; Cappola TP; Hernandez AF; Scott CG; Burnett JC; Pereira NL
JACC Heart Fail; 2020 Jan; 8(1):70-80. PubMed ID: 31392960
[TBL] [Abstract][Full Text] [Related]
64. Echocardiographic assessment of insulin-like growth factor binding protein-7 and early identification of acute heart failure.
Kalayci A; Peacock WF; Nagurney JT; Hollander JE; Levy PD; Singer AJ; Shapiro NI; Cheng RK; Cannon CM; Blomkalns AL; Walters EL; Christenson RH; Chen-Tournoux A; Nowak RM; Lurie MD; Pang PS; Kastner P; Masson S; Gibson CM; Gaggin HK; Januzzi JL
ESC Heart Fail; 2020 Aug; 7(4):1664-1675. PubMed ID: 32406612
[TBL] [Abstract][Full Text] [Related]
65. Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study.
Cleland JG; Taylor J; Freemantle N; Goode KM; Rigby AS; Tendera M
Eur J Heart Fail; 2012 May; 14(5):487-94. PubMed ID: 22505395
[TBL] [Abstract][Full Text] [Related]
66. An altered plasma lipidome-phenome network characterizes heart failure with preserved ejection fraction.
Jovanovic N; Foryst-Ludwig A; Klose C; da Conceicao CR; Alasfar L; Birkner T; Forslund SK; Kintscher U; Edelmann F
ESC Heart Fail; 2024 Jun; 11(3):1553-1566. PubMed ID: 38243357
[TBL] [Abstract][Full Text] [Related]
67. Usefulness of tissue Doppler imaging-myocardial performance index in the evaluation of diastolic dysfunction and heart failure with preserved ejection fraction.
Kim H; Yoon HJ; Park HS; Cho YK; Nam CW; Hur SH; Kim YN; Kim KB
Clin Cardiol; 2011 Aug; 34(8):494-9. PubMed ID: 21780137
[TBL] [Abstract][Full Text] [Related]
68. Exercise training in heart failure with preserved systolic function: a randomized controlled trial of the effects on cardiac function and functional capacity.
Smart NA; Haluska B; Jeffriess L; Leung D
Congest Heart Fail; 2012; 18(6):295-301. PubMed ID: 22536983
[TBL] [Abstract][Full Text] [Related]
69. Diastolic stress test echocardiography in patients with suspected heart failure with preserved ejection fraction: a pilot study.
Belyavskiy E; Morris DA; Url-Michitsch M; Verheyen N; Meinitzer A; Radhakrishnan AK; Kropf M; Frydas A; Ovchinnikov AG; Schmidt A; Tadic M; Genger M; Lindhorst R; Bobenko A; Tschöpe C; Edelmann F; Pieske-Kraigher E; Pieske B
ESC Heart Fail; 2019 Feb; 6(1):146-153. PubMed ID: 30451399
[TBL] [Abstract][Full Text] [Related]
70. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
[TBL] [Abstract][Full Text] [Related]
71. Clinical, Demographic, and Imaging Correlates of Anemia in Heart Failure With Preserved Ejection Fraction (from the RELAX Trial).
Parcha V; Patel N; Kalra R; Bhargava A; Prabhu SD; Arora G; Arora P
Am J Cardiol; 2020 Jun; 125(12):1870-1878. PubMed ID: 32307089
[TBL] [Abstract][Full Text] [Related]
72. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
[TBL] [Abstract][Full Text] [Related]
73. Insulin-like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence.
Bracun V; van Essen B; Voors AA; van Veldhuisen DJ; Dickstein K; Zannad F; Metra M; Anker S; Samani NJ; Ponikowski P; Filippatos G; Cleland JGF; Lang CC; Ng LL; Shi C; de Wit S; Aboumsallem JP; Meijers WC; Klip IT; van der Meer P; de Boer RA
ESC Heart Fail; 2022 Dec; 9(6):4167-4176. PubMed ID: 36088651
[TBL] [Abstract][Full Text] [Related]
74. Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial.
Samuel TY; Hasin T; Gotsman I; Weitzman T; Ben Ivgi F; Dadon Z; Asher E; Amir O; Glikson M; Alcalai R; Leibowitz D
Drugs R D; 2022 Mar; 22(1):25-33. PubMed ID: 34826125
[TBL] [Abstract][Full Text] [Related]
75. Different implication of elevated B-type natriuretic peptide level in patients with heart failure with preserved ejection fraction and in those with reduced ejection fraction.
Ishigaki T; Yoshida T; Izumi H; Fujisawa Y; Shimizu S; Masuda K; Asanuma T; Okabe H; Nakatani S
Echocardiography; 2015 Apr; 32(4):623-9. PubMed ID: 25115860
[TBL] [Abstract][Full Text] [Related]
76. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
Hoendermis ES; Liu LC; Hummel YM; van der Meer P; de Boer RA; Berger RM; van Veldhuisen DJ; Voors AA
Eur Heart J; 2015 Oct; 36(38):2565-73. PubMed ID: 26188003
[TBL] [Abstract][Full Text] [Related]
77. Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of Heart Failure With Preserved Ejection Fraction: Rationale and Study Design of a Prospective Randomized Controlled Trial.
Palau P; Domínguez E; López L; Heredia R; González J; Ramón JM; Serra P; Santas E; Bodi V; Sanchis J; Chorro FJ; Núñez J
Clin Cardiol; 2016 Aug; 39(8):433-9. PubMed ID: 27481035
[TBL] [Abstract][Full Text] [Related]
78. Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity.
Reddy YNV; Rikhi A; Obokata M; Shah SJ; Lewis GD; AbouEzzedine OF; Dunlay S; McNulty S; Chakraborty H; Stevenson LW; Redfield MM; Borlaug BA
Eur J Heart Fail; 2020 Jun; 22(6):1009-1018. PubMed ID: 32150314
[TBL] [Abstract][Full Text] [Related]
79. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH
J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053
[TBL] [Abstract][Full Text] [Related]
80. Relationship Between Focal and Diffuse Fibrosis Assessed by CMR and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.
Kanagala P; Cheng ASH; Singh A; Khan JN; Gulsin GS; Patel P; Gupta P; Arnold JR; Squire IB; Ng LL; McCann GP
JACC Cardiovasc Imaging; 2019 Nov; 12(11 Pt 2):2291-2301. PubMed ID: 30772227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
